Journal ArticleDOI
Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Emily M. Hawes,Allison M. Deal,D. Funk-Adcock,Robert C. Gosselin,C. Jeanneret,A. M. Cook,J. M. Taylor,Herbert C. Whinna,A. M. Winkler,Stephan Moll +9 more
Reads0
Chats0
TLDR
Knowledge of anticoagulation status during dabigatran therapy may be desirable in certain clinical situations.About:
This article is published in Journal of Thrombosis and Haemostasis.The article was published on 2013-08-01. It has received 226 citations till now. The article focuses on the topics: Ecarin clotting time & Dabigatran.read more
Citations
More filters
Journal ArticleDOI
Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
TL;DR: Dabigatran, rivaroxaban, and apixaban exhibit variable effects on coagulation assays and understanding these effects facilitates interpretation of test results in NOAC-treated patients.
Journal ArticleDOI
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
Karlyn Martin,Jan Beyer-Westendorf,Bruce L. Davidson,Menno V. Huisman,Per Morten Sandset,Stephan Moll +5 more
TL;DR: This work presents a novel and exciting new approach to thrombosis research that aims to provide real-time information about the progression of blood clotting problems in patients with deep vein thrombus.
Journal ArticleDOI
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants.
Robert C. Gosselin,Dorothy M. Adcock,Shannon M. Bates,Jonathan Douxfils,Emmanuel J. Favaloro,Isabelle Gouin-Thibault,Cecilia Guillermo,Yohko Kawai,Edelgard Lindhoff-Last,Steve Kitchen +9 more
TL;DR: This inaugural coagulation ICSH document was developed by an ad hoc committee, comprised of international clinical and laboratory direct acting oral anticoagulant (DOAC) experts, and provided recommendations for the proper validation or verification of performance of laboratory assays prior to implementation for clinical use and external quality assurance.
Journal ArticleDOI
Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review
TL;DR: An ideal test, offering both accuracy and precision for measurement of any DOAC is not widely available, and a dilute TT or ecarin‐based assay for assessment of the anticoagulant effect of dabigatran and anti‐Xa assays with drug‐specific calibrators for direct Xa inhibitors is recommended.
Journal ArticleDOI
Determination of dabigatran, rivaroxaban and apixaban by ultra‐performance liquid chromatography – tandem mass spectrometry (UPLC‐MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants
E Ellen Schmitz,K Koen Boonen,van den Dja Heuvel,van Jlj Joost Dongen,Mwm Schellings,Jhpm Jack Emmen,van der F Graaf,Luc Brunsveld,van de Dh Daan Kerkhof +8 more
TL;DR: Three novel direct oral anticoagulants (DOACs) have recently been registered by the Food and Drug Administration and European Medicines Agency Commission: dabigatran, rivaroxaban, and apixaban.
References
More filters
Journal ArticleDOI
Dabigatran versus warfarin in patients with atrial fibrillation
Stuart J. Connolly,Michael D. Ezekowitz,John W. Eikelboom,Jonas Oldgren,Amit Parekh,Janice Pogue,Paul A. Reilly,Ellison Themeles,Jeanne Varrone,Susan Wang,Marco Alings,Denis Xavier,Jun Zhu,Rafael Diaz,Basil S. Lewis,Harald Darius,Hans-Christoph Diener,Campbell D. Joyner,Lars Wallentin +18 more
TL;DR: In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.
Journal ArticleDOI
Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
Joanne van Ryn,Joachim Stangier,Sebastian Haertter,Karl-Heinz Liesenfeld,Wolfgang Wienen,Martin Feuring,Andreas Clemens +6 more
TL;DR: Although there is no specific antidote to antagonise the anticoagulant effect of dabigatran, due to its short duration of effect drug discontinuation is usually sufficient to reverse any excessive anticogulant activity.
Journal ArticleDOI
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
TL;DR: Results obtained so far show that dabigatran etexilate is well tolerated and effective in the treatment and prevention of thromboembolic events.
Journal ArticleDOI
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).
Michael D. Ezekowitz,Paul A. Reilly,Gerhard Nehmiz,Timothy A. Simmers,Rangadham Nagarakanti,Kambiz Parcham-Azad,K. Erik Pedersen,Dominick A. Lionetti,Joachim Stangier,Lars Wallentin +9 more
TL;DR: Dabigatran plasma concentrations, activated partial thromboplastin time, D-dimer, urinary 11-dehydrothromboxane B(2) (DTB2), and liver function were measured at baseline and at 1, 2, 4, 8, and 12 weeks and the significance of the increase of DTB2 concentrations in dabig atran-treated patients needs resolution.
Journal ArticleDOI
Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Jonathan Douxfils,François Mullier,Séverine Robert,Christian Chatelain,Bernard Chatelain,Jean-Michel Dogné +5 more
TL;DR: APTT could be used for the monitoring of dabigatran and as screening test for the risk of overdose and HTI should be considered as the gold-standard because of its higher sensitivity, good reproducibility, excellent linear correlation at all doses, its simplicity of use, and possibilities of automation.